16.42
-0.52 (-3.07%)
| Previous Close | 16.94 |
| Open | 16.36 |
| Volume | 825,454 |
| Avg. Volume (3M) | 190,251 |
| Market Cap | 558,545,984 |
| Price / Book | 2.36 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -2.56 |
| Total Debt/Equity (MRQ) | 0.07% |
| Current Ratio (MRQ) | 13.14 |
| Operating Cash Flow (TTM) | -70.21 M |
| Levered Free Cash Flow (TTM) | -48.64 M |
| Return on Assets (TTM) | -26.91% |
| Return on Equity (TTM) | -39.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ArriVent BioPharma, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.72% |
| % Held by Institutions | 84.59% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Guggenheim, 174.06%) | Buy |
| Median | 39.00 (137.52%) | |
| Low | 37.00 (B. Riley Securities, 125.34%) | Buy |
| Average | 40.33 (145.62%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 21.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 20 Mar 2025 | 37.00 (125.33%) | Buy | 19.54 |
| Guggenheim | 10 Mar 2025 | 45.00 (174.06%) | Buy | 21.73 |
| HC Wainwright & Co. | 07 Mar 2025 | 39.00 (137.52%) | Buy | 21.87 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Apr 2025 | Announcement | ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors |
| 03 Mar 2025 | Announcement | ArriVent BioPharma Reports Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |